BackgroundThird-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of NSCLC with EGFR mutati Abstract Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of NSCLC with...
Summary Kinase inhibitors are commonly used in research and clinical practice. Among them, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as afatinib and osimertinib, constitute an important subclass. The aim of this study was to create...
Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a major clinical challenge in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). This study established TKI-resistant variants by integrating cell lines, lung cancer organoids (LCOs), and in vivo models, revealing...
Abstract Rivaroxaban dosing for nonvalvular atrial fibrillation (NVAF) is based on Cockcroft–Gault creatinine clearance using actual body weight (CG-CrCl-ABW) per FDA labeling. Recent recommendations support utilizing the race-free CKD-EPI 2021 equation for estimating kidney function. However, it is unknown whether...
Original Article Share on Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCAuthors: Pasi A. Jänne, M.D., Ph.D., David Planchard, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Ying Liu, M.D., Natalia Valdiviezo, M.D., Tae Min Kim,...
Abstract EGFR exon 20 insertion (ex20ins) NSCLC typically shows limited response to immunotherapy. We report a rare case of a smoker with metastatic EGFR ex20ins (p.S768_D770dup) and high PD-L1 expression (TPS 50%) who achieved exceptional survival (OS = 63 months)....
Syndax Pharmaceuticals recently held an R&D event where it outlined its late-stage programs, including revumenib and axatilimab, and introduced two new candidates: SNDX-4321, an allosteric EGFR inhibitor for EGFR-mutant NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis, with multiple...
This is a preview of subscription content, log in via an institution to check access. Access this article Log in via an institution Subscribe and save Springer+ from €39.99 /Month Starting from 10 chapters or articles per month Access and...
